EFM
CMPX icon

E Fund Management’s Compass Therapeutics CMPX Stock Holding History

E Fund Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$130K Buy
+24,622
New +$142K ﹤0.01% 466

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

E Fund Management's CMPX Position: Q1 2026 in Review

E Fund Management opened a new position in Compass Therapeutics (CMPX) in Q1 2026: 24,622 shares worth $130K. The stake represents ﹤0.01% of the portfolio and ranks #466 among its holdings.

201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • E Fund Management held 24,622 shares of Compass Therapeutics worth $130K as of Q1 2026.
  • Compass Therapeutics was a new E Fund Management position in Q1 2026.
  • Compass Therapeutics made up ﹤0.01% of E Fund Management's portfolio in Q1 2026, its #466 holding.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on E Fund Management's 13F filing for Q1 2026, filed 13 Apr 2026.